肺癌
医学
地图集(解剖学)
肿瘤科
转移
腺癌
内科学
逃避(道德)
免疫系统
癌症研究
免疫疗法
癌症
肿瘤微环境
总体生存率
细胞
生物信息学
生物
疾病
转录组
无线电技术
炎症
作者
Philipp Sebastian Jurmeister,Philipp Keyl,Liliana Harris Mochmann,Linda Bergmayr,Konstanze Schleich,Edgar Chimal,Fabian Engelhardt-Schott,Doreen Klingler,Dražen Papić,Janine Wolff,Rebecca Fritz,Julius Keyl,Sabine Merkelbach‐Bruse,Alexander Quaas,Georg Schlachtenberger,Matthias B. Heldwein,Jens‐Carsten Rückert,Gabriel Dernbach,Nils Reinmuth,Christian Grohé
标识
DOI:10.1038/s43018-026-01260-w
摘要
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, characterized by extensive cellular and molecular heterogeneity. Here, to capture this complexity, we present LuCaS+, a multicenter single-cell RNA sequencing atlas comprising over 2.5 million nuclei from 454 clinically annotated patients with NSCLC with long-term follow-up. LuCaS+ consists of a discovery dataset (Berlin and Cologne, 364 patients) and an independent validation dataset (Munich, 90 patients). Leveraging this dataset, we identified tumor subpopulations with high metastatic potential associated with oncogenic signaling, immune evasion and epithelial-mesenchymal transition. In early-stage adenocarcinoma (lung adenocarcinoma), these cells showed strong prognostic value. Integrating tumor and microenvironmental cell profiles improved survival prediction across all stages, identifying distinct tumor-immune-stromal interaction patterns. These included monocyte- and fibroblast-driven inflammation (lung adenocarcinoma), VEGF-TGFβ-mediated angiogenic feedback loops (lung squamous cell carcinoma) and immune-permissive niches promoting antitumor immunity. LuCaS+ offers a clinically anchored single-cell resource to enable personalized, biology-driven therapies in NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI